Cargando…
Tumor cells have decreased ability to metabolize H(2)O(2): Implications for pharmacological ascorbate in cancer therapy
Ascorbate (AscH(−)) functions as a versatile reducing agent. At pharmacological doses (P-AscH(−); [plasma AscH(−)] ≥≈20 mM), achievable through intravenous delivery, oxidation of P-AscH(−) can produce a high flux of H(2)O(2) in tumors. Catalase is the major enzyme for detoxifying high concentrations...
Autores principales: | Doskey, Claire M., Buranasudja, Visarut, Wagner, Brett A., Wilkes, Justin G., Du, Juan, Cullen, Joseph J., Buettner, Garry R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106370/ https://www.ncbi.nlm.nih.gov/pubmed/27833040 http://dx.doi.org/10.1016/j.redox.2016.10.010 |
Ejemplares similares
-
Pharmacological ascorbate and ionizing radiation (IR) increase labile iron in pancreatic cancer()
por: Moser, Justin C., et al.
Publicado: (2013) -
The role of mitochondria in pharmacological ascorbate-induced toxicity
por: Du, Juan, et al.
Publicado: (2022) -
Catalase Modulates the Radio-Sensitization of Pancreatic Cancer Cells by Pharmacological Ascorbate
por: Du, Juan, et al.
Publicado: (2021) -
Pharmacological Ascorbate Elicits Anti-Cancer Activities against Non-Small Cell Lung Cancer through Hydrogen-Peroxide-Induced-DNA-Damage
por: Sanookpan, Kittipong, et al.
Publicado: (2023) -
Stability of aqueous solutions of ascorbate for basic research and for intravenous administration
por: Wagner, Brett A., et al.
Publicado: (2023)